Top 10 Companies in the Global Antisense and RNAi Therapeutics Market:(2025-2035): Expert View by Spherical Insights
RELEASE DATE: Mar 2026 Author: Spherical InsightsRequest Free Sample Speak to Analyst
Introduction
Antisense and RNA interference (RNAi) therapies are effective because they suppress the expression of disease-related genes. The application of antisense and RNAi medicines to better treatment results for rare disorders is one of the main forces driving the growth of the market under investigation. The availability of possible pipeline items and increasing R&D expenditures are among other elements supporting the expansion of the market. Treatment of rare and orphan diseases with minimal available therapy, such as familial chylomicronemia syndrome (FCS), spinal muscular atrophy (SMA), and transthyretin amyloidosis (ATTR), has shown excellent treatment capacity using RNA interference (RNAi) and antisense pharmaceuticals. Pharmaceutical companies find these conditions attractive since they allow early proof-of-concept and commercialization with modest trials.
Furthermore, rapid market growth is governed by the creation of new drug delivery methods for the efficient delivery of RNA interference and antisense treatments. Traditional delivery method consisting of intravenous injection has presented major obstacles to bioavailability as they are tough to cross cell membranes and swiftly degraded by blood nucleases. Advances in material science and nanotechnology, however, have made it possible to create sophisticated carrier systems that promote cellular uptake while shielding oligonucleotides from degradation.
Navigate Future Markets with Confidence: Insights from Spherical Insights LLP
The insights presented in this blog are derived from comprehensive market research conducted by Spherical Insights LLP, a trusted advisory partner to leading global enterprises. Backed by in-depth data analysis, expert forecasting, and industry-specific intelligence, our reports empower decision-makers to identify strategic growth opportunities in fast-evolving sectors. Clients seeking detailed market segmentation, competitive landscapes, regional outlooks, and future investment trends will find immense value in the full report. By leveraging our research, businesses can make informed decisions, gain a competitive edge, and stay ahead in the transition toward sustainable and profitable solutions.
Unlock exclusive market insights-Download the Brochure now and dive deeper into the future of The Global Antisense and RNAi Therapeutics Market
Antisense and RNAi Therapeutics Market Size & Statistics
- The Market Size for Antisense and RNAi Therapeutics Was Estimated to be worth USD 5.08 Billion in 2024.
- The Market Size is Going to Expand at a CAGR of 19.3% between 2025 and 2035.
- The Global Antisense and RNAi Therapeutics Market Size is anticipated to reach USD 35.39 Billion by 2035.
- North America is estimated to dominate the market during the forecast period in the Antisense and RNAi Therapeutics Market.
- Asia-Pacific is projected to grow the fastest during the forecast period in the Antisense and RNAi Therapeutics Market.
Regional growth and demand
North America is expected to dominate the market during the forecast period in the Antisense and RNAi Therapeutics market.
North America held the majority of the market share by revenue for 2024 and is expected to grow significantly during the forecast period. The market growth in North America is attributed to the significant presence of leading biopharma companies and excellent research institutions in countries like the United States. Many companies have made significant investments in R&D to develop innovative RNAi-based medicines. CRISPR-based systems require antisense and RNA interference (RNAi) therapies, which have a wide range of uses in research and possibly in therapy. Businesses engaged in gene editing, biotechnology, and life sciences are important market participants. The demand for antisense and RNA interference (RNAi) treatments that target genes associated with various genetic disorders is expected to increase as new products are approved.
Asia-Pacific is projected to grow the fastest during the forecast period in the Antisense and RNAi Therapeutics market.
Asia-Pacific is projected to grow the fastest during the forecast period in the Antisense and RNAi Therapeutics market. The presence of many companies that focus on RNA interference and antisense therapies is anticipated to drive regional growth. Additionally, these businesses are working on a number of projects to increase the variety of goods and business prospects they offer.
Ready to lead the Antisense and RNAi Therapeutics Market?
Discover the regional trends and growth factors shaping the industry. We’re here to assist with expert, personalized data.
Call +1 303 800 4326 or Send us a message for a personalized consultation.
Top 10 Trends in the Antisense and RNAi Therapeutics Market
- Revolutionary Delivery Technologies
- Focus on uncommon and Genetic Disorders
- Increasing Cardiovascular and Metabolic Diseases
- Growth of CNS Therapies
- AI-Driven Target Selection
- Combination Therapies
- Personalised Medicine
- Acceleration of Regulatory Approvals
- Manufacturing Scaling
- Growth in Oncology Applications
1.Revolutionary Delivery Technologies
By overcoming earlier obstacles in bioavailability, developments in LNP and GalNAc technology are dramatically improving stability, specificity, and delivery efficiency (up to 45%).
2.Focus on uncommon and Genetic Disorders
With many treatments being designated as orphan drugs, the market is primarily focused on meeting the significant unmet needs in uncommon diseases.
3.Increasing Cardiovascular and Metabolic Diseases
RNA interference (RNAi) is being used for a growing number of patients, especially to decrease cholesterol and control cardiometabolic conditions. Rapid acceptance is anticipated.
4.Growth of CNS Therapies
Advances in the treatment of neurological conditions, including Alzheimer, Huntington, and ALS, are being fuelled by intrathecal injections.
5.AI-Driven Target Selection
To optimise oligonucleotide sequence design, minimise off-target effects, and expedite research, artificial intelligence and machine learning are being used more and more.
Empower your strategic planning:
Stay informed with the latest industry insights and market trends to identify new opportunities and drive growth in the anti-Venom market. To explore more in-depth trends, insights, and forecasts, please refer to our detailed report.
Unlock exclusive market insights-Download the Brochure now and dive deeper into the future of The Global Antisense and RNAi Therapeutics Market
Top 10 Companies Leading the Antisense and RNAi Therapeutics Market
- Alnylam Pharmaceuticals
- Sarepta Therapeutics
- Ionis Pharmaceuticals
- Arrowhead Pharmaceuticals
- Dicerna (Novo Nordisk)
- Sirnaomics
- Silence Therapeutics
- Arbutus Biopharma
- OliX Pharmaceuticals
- Benitec Biophatma
1.Alnylam Pharmaceuticals
Headquarters: Cambridge, USA
Founded in 2002, Alnylam is a US -based business. Its associated product line comprises onpattro, amvuttra, givlaari, and oxlumo, and in 2024, its total income was about $2.25 billion. Furthermore, it has great R&D focus and investment and runs in over 25 nations. Furthermore, it is a world leader in RNAi; its GalNAc platform increases liver targeting by 70%.
2.Sarepta Therapeutics
Headquarters: Cambridge, USA
It is an establishment of 1980 with revenue for the year 2024 estimated to be approximately of $1.90 billion. Its core product range consists of elevidys (gene therapy), exondys 51, vyondys 53, amondys 45. The majority of its working sites are in the USA. Moreover, it has excellent dominance in the Duchenne muscular dystrophy market with RNA-based PMOs.
3.Ionis Pharmaceuticals
Headquarters: Mumbai, India
It discovered antisense technology with a significant 80+ drug pipeline. It was established in 1989 and currently, has its business operations are based in Carlsbad, USA. It specialises in sprinraza (with biogen), wainua, tryngolza, qalsody. Its 2024 gross revenue was around $705.1 million.
4.Arrowhead Pharmaceuticals
Headquarters: Pasadena, CA, USA
It is an establishment of 1989 and had revenue of $350 Million in 2024 through its operations. It is product portfolio consist of plozasiran, (cardiometabolic), and aro-rage (pulmonary). Moreover, it applies TRiM platform for tissue-centric delivery beyond the liver.
5.Dicerna (Novo Nordisk)
Headquarters: Pennsylvania, USA
The company was started in 2007, and its recent revenue was of $250 million for 2024 and has a core product portfolio consisting of rivfloza and belcesiran. Moreover, it has business operating globally under Novo Nordisk. Moreover, it was recently acquired by Novo Nordisk, whereas its works mostly related to GALXC RNAi platform.
Are you ready to discover more about the Antisense and RNAi Therapeutics Market?
The report provides an in-depth analysis of the leading companies operating in the global Antisense and RNAi Therapeutics market. It includes a comparative assessment based on their product portfolios, business overviews, geographical footprint, strategic initiatives, market segment share, and SWOT analysis. Each company is profiled using a standardised format that includes:
Unlock exclusive market insights-Download the Brochure now and dive deeper into the future of The Global Antisense and RNAi Therapeutics Market
Company Profile
- Alnylam Pharmaceuticals
- Business Overview
- Company Snapshot
- Products Overview
- Company Market Share Analysis
- Company Coverage Portfolio
- Financial Analysis
- Recent Developments
- Merger and Acquisitions
- SWOT Analysis
Our Report
https://www.sphericalinsights.com/reports/united-kingdom-hysteroscopy-procedures-market
https://www.sphericalinsights.com/reports/united-states-luxury-goods-market
https://www.sphericalinsights.com/reports/united-kingdom-makgeolli-market
https://www.sphericalinsights.com/reports/vietnam-ammonia-market
Conclusion
The Global Antisense and RNAi Therapeutics Market size is expected to grow at a compound annual growth rate (CAGR) of 19.3%, from USD 5.08 billion in 2024 to USD 35.39 billion by 2035. Global market expansion is fuelled by Global market expansion is fuelled by effective suppression of the expression of disease-related genes, increased focus on orphan and rare indicators, innovation in drug delivery methods, research and development. North America holds majority of regions shares, which is due to the significant presence of leading biopharma companies and excellent research institutions in countries like the United States. Asia-Pacific is projected to grow the fastest during the forecast period due to the presence of many companies that focus on RNA interference and antisense therapies is anticipated to drive regional growth.
About the Spherical Insights & Consulting
Spherical Insights & Consulting is a market research and consulting firm which provides actionable market research study, quantitative forecasting and trends analysis provides forward-looking insight especially designed for decision makers and aids ROI.
Which is catering to different industry such as financial sectors, industrial sectors, government organizations, universities, non-profits and corporations. The company's mission is to work with businesses to achieve business objectives and maintain strategic improvements.
CONTACT US:
For More Information on Your Target Market, Please Contact Us Below:
Phone: +1 303 800 4326 (the U.S.)
Phone: +91 90289 24100 (APAC)
Email: inquiry@sphericalinsights.com, sales@sphericalinsights.com
Contact Us: https://www.sphericalinsights.com/contact-us
Need help to buy this report?